Twenty-year survivors of heart transplantation at Stanford University

Am J Transplant. 2008 Sep;8(9):1769-74. doi: 10.1111/j.1600-6143.2008.02310.x. Epub 2008 Jun 12.

Abstract

Human heart transplantation started 40 years ago. Medical records of all cardiac transplants performed at Stanford were reviewed. A total of 1446 heart transplantations have been performed between January 1968 and December 2007 with an increase of 1-year survival from 43.1% to 90.2%. Sixty patients who were transplanted between 1968 and 1987 were identified who survived at least 20 years. Twenty-year survivors had a mean age at transplant of 29.4 +/- 13.6 years. Rejection-free and infection-free 1-year survivals were 14.3% and 18.8%, respectively. At their last follow-up, 86.7% of long-term survivors were treated for hypertension, 28.3% showed chronic renal dysfunction, 6.7% required hemodialysis, 10% were status postkidney transplantation, 13.3% were treated for diabetes mellitus, 36.7% had a history of malignancy and 43.3% had evidence of allograft vasculopathy. The half-life conditional on survival to 20 years was 28.1 years. Eleven patients received a second heart transplant after 11.9 +/- 8.0 years. The most common causes of death were allograft vasculopathy (56.3%) and nonlymphoid malignancy (25.0%). Twenty-year survival was achieved in 12.5% of patients transplanted before 1988. Although still associated with considerable morbidity, long-term survival is expected to occur at much higher rates in the future due to major advances in the field over the past decade.

MeSH terms

  • Academic Medical Centers*
  • Adolescent
  • Adult
  • Female
  • Graft Rejection / epidemiology*
  • Graft Rejection / surgery*
  • Graft Survival
  • Heart Transplantation / mortality*
  • Heart Transplantation / statistics & numerical data
  • Humans
  • Immunosuppression Therapy
  • Immunosuppressive Agents
  • Male
  • Morbidity
  • Survival Analysis
  • Survivors*
  • United States / epidemiology

Substances

  • Immunosuppressive Agents